SD Biosensor Inc Cash Flow Conversion Efficiency
SD Biosensor Inc cash flow conversion efficiency. Based on the latest financial reports, SD Biosensor Inc (137310) has a cash flow conversion efficiency ratio of 0.001x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.55 Billion ≈ $1.05 Million USD) by net assets (₩2.41 Trillion ≈ $1.63 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of SD Biosensor Inc (2019–2025)
Cash flow conversion efficiency of SD Biosensor Inc from 2019 to 2025. This chart illustrates how SD Biosensor Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SD Biosensor Inc stock price for real-time trading data and today's change.
SD Biosensor Inc Cash Flow Conversion Ratio Explained
SD Biosensor Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
SD Biosensor Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SD Biosensor Inc ranked by their cash flow conversion efficiency. Also see SD Biosensor Inc (137310) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
United States Cellular Corporation
NYSE:USM
|
-0.100x |
|
Indigo Paints Limited
NSE:INDIGOPNTS
|
0.027x |
|
Shenzhen Jasic Tech Co
SHE:300193
|
0.030x |
|
Prism Johnson Limited
NSE:PRSMJOHNSN
|
-0.043x |
|
goeasy Ltd
TO:GSY
|
0.228x |
|
Sunrise Energy Metals Ltd
AU:SRL
|
-0.278x |
|
Capital Bancorp
NASDAQ:CBNK
|
0.053x |
|
Jinhe Biotechnology Co Ltd
SHE:002688
|
0.088x |
Annual Cash Flow Conversion Efficiency for SD Biosensor Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of SD Biosensor Inc from 2019 to 2025. Review SD Biosensor Inc (137310) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩2.34 Trillion ≈ $1.58 Billion |
₩357.52 Billion ≈ $242.28 Million |
0.153x | +186.60% |
| 2024-12-31 | ₩2.93 Trillion ≈ $1.99 Billion |
₩156.53 Billion ≈ $106.08 Million |
0.053x | +162.38% |
| 2023-12-31 | ₩2.83 Trillion ≈ $1.92 Billion |
₩-242.32 Billion ≈ $-164.22 Million |
-0.086x | -128.33% |
| 2022-12-31 | ₩2.95 Trillion ≈ $2.00 Billion |
₩890.23 Billion ≈ $603.30 Million |
0.302x | -46.10% |
| 2021-12-31 | ₩2.20 Trillion ≈ $1.49 Billion |
₩1.23 Trillion ≈ $836.90 Million |
0.560x | -14.29% |
| 2020-12-31 | ₩757.55 Billion ≈ $513.38 Million |
₩495.38 Billion ≈ $335.71 Million |
0.654x | +5650.64% |
| 2019-12-31 | ₩137.91 Billion ≈ $93.46 Million |
₩-1.62 Billion ≈ $-1.10 Million |
-0.012x | -- |
About SD Biosensor Inc
SD Biosensor, Inc., together with its subsidiaries, operates as an in-vitro diagnostic company in South Korea, India, Asia, Europe, the Americas, and Africa. The company offers STANDARD Q, which provides rapid diagnostic products; STANDARD F, a fluorescence immunodiagnostic system for various qualitative and quantitative diagnosis items; STANDARD E, an enzyme immunoassay diagnosis for large-volum… Read more